Cooper Companies (COO) Stock Forecast & Price Target

Cooper Companies is the US's largest eyecare company, with a suite of spherical, multifocal, and toric contact lenses and the most comprehensive specialty lens portfolio in the world. Their CooperVision segment controls 25% of the US contact lens market and their CooperSurgical segment, focused on reproductive and women's care, covers the entire IVF cycle and controls 17% of the US IUD market. Their recent revenue and EPS beat reflects strong growth in both segments, and despite lowering their FY26 revenue guidance due to APAC challenges, their operating margin and interest expense reduction suggest high-single digit or better EPS growth. Risks such as increasing competition and currency headwinds could impact their growth, but their strong market presence and diversified product portfolio make Cooper Companies a solid investment opportunity.

Cooper Companies is a well-established eyecare company that has a diverse portfolio of products in both the contact lens and medical device segments. However, with lower revenue and EPS projections for the next few years, combined with a lukewarm response from investors for a potential sale of the company, the negative outlook is driven by concerns about the company's long-term growth potential and ability to effectively maximize shareholder value. The recent rollout of MyDay MiSight at a similar price point to its predecessor highlights potential limitations to the company's pricing power and the need to drive market share through other means.